Hsieh, James J.
Purdue, Mark P.
Signoretti, Sabina
Swanton, Charles
Albiges, Laurence
Schmidinger, Manuela
Heng, Daniel Y.
Larkin, James
Ficarra, Vincenzo
Article History
First Online: 9 March 2017
Competing interests
: J.J.H. is a consultant for Novartis, Eisai and Chugai and has received research funding from Pfizer, Novartis, Eisai and Cancer Genomics Inc. C.S. is a consultant for Roche, Pfizer, Boehringer Ingelheim, Novartis, Celgene, Servler, Eli Lilly and GlaxoSmithKline, and owns stock options from Achilles Therapeutics, Epic Biosciences, Grail and ApoGen Biotech. L.A. is a consultant for Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer and Cerulean, and has received research funding from Pfizer and Novartis. M.S. is a consultant for Pfizer, Bristol-Myers Squibb, Ipsen, Exelixis, Eisai, Roche, Novartis and Astellas. D.Y.H. is a consultant for Pfizer, Novartis and Bristol-Myers Squibb. J.L. has received research funding from Novartis, Pfizer, Bristol-Myers Squibb and Merck Sharp & Dohme. M.P.P., S.S. and V.F. declare no competing interests.